Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs

Journal of the National Cancer Institute

Volumn 105, Issue 17, 2013, Pages 1322-1331

  Tannous, Bakhos A ^b   Kerami, Mariam ^b   Van Der Stoop, Petra M ^b   Kwiatkowski, Nicholas ^b   Wang, Jinhua ^b   Zhou, Wenjun ^b   Kessler, Almuth F ^b   Lewandrowski, Grant ^b   Hiddingh, Lotte ^b   Sol, Nik ^b   Lagerweij, Tonny ^b   Wedekind, Laurine ^b   Niers, Johanna M ^b   Barazas, Marco ^b   Nilsson, R Jonas A ^b   Geerts, Dirk ^b   De Witt Hamer, Philip C ^b   Hagemann, Carsten ^b   Vandertop, W Peter ^b   Van Tellingen, Olaf ^b   Noske, David P ^b   Gray, Nathanael S ^b   Würdinger, Thomas ^a   more..

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; ENZYME; MONOPOLAR SPINDLE 1; PACLITAXEL; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; VINCRISTINE;

ANEUPLOIDY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GRADING; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DRUG SENSITIZATION; GENE EXPRESSION; GLIOBLASTOMA; MITOSIS; NONHUMAN; PATIENT; PRIORITY JOURNAL; RAT; RNA INTERFERENCE; SURVIVAL; SURVIVAL RATE;

2-AMINOPURINE; ANIMALS; ANTIMITOTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE PROTEINS; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FRANCE; FROZEN SECTIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; MICE; MICE, NUDE; NETHERLANDS; ORTHO-AMINOBENZOATES; PACLITAXEL; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; RNA INTERFERENCE; UNITED STATES; UP-REGULATION; VINCRISTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884490796     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt168     Document Type: Article

References (43)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
2. Thomas D, Brada M, Stenning S. Randomized trial of porcarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: A medical research council trial. J Clin Oncol. 2001;19(2):509-518.
3. Fetell MR, Grossman SA, Fisher JD, et al. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. J Clin Oncol. 1997;15(9):3121-3128.
4. Mir SE, de Witt Hamer PC, Krawczyk PM, et al. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell. 2010;18(3):244-257.
5. Fisk HA, Mattison CP, Winey M. A field guide to the Mps1 family of protein kinases. Cell Cycle. 2004;3(4):439-442.
6. Musacchio A and Salmon ED. The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol. 2007;8(5):379-393.
7. Tighe A, Staples O, Taylor S. Mps1 kinase activity restrains anaphase during an unperturbed mitosis and targets Mad2 to kinetochores. J Cell Biol. 2008;181(6):893-901.
8. Maciejowski J, George KA, Terret ME, et al. Mps1 directs the assembly of Cdc20 inhibitory complexes during interphase and mitosis to control M phase timing and spindle checkpoint signaling. J Cell Biol. 2010;190(1):89-100.
9. Maure JF, Kitamura E, Tanaka TU. Mps1 kinase promotes sister-kinetochore bi-orientation by a tension-dependent mechanism. Curr Biol. 2007;17(24):2175- 2182.
10. Jelluma N, Brenkman AB, McLeod I, et al. Chromosomal instability by inefficient Mps1 auto-activation due to a weakened mitotic checkpoint and lagging chromosomes. PLoS One. 2008;3(6):e2415.
11. Jelluma N, Brenkman AB, van den Broek NJ, et al. Mps1 phosphorylates borealin to control aurora B activity and chromosome alignment. Cell. 2008;132(2):233-246.
12. Santaguida S, Tighe A, D'Alise AM, Taylor SS, Musacchio A. Dissecting the role of MPS1 in chromosome biorientation and the spindle checkpoint through the small molecule inhibitor reversine. J Cell Biol. 2010;190(1):73-87.
13. Huang YF, Chang MD, Shieh SY. TTK/hMps1 mediates the p53-dependent postmitotic checkpoint by phosphorylating p53 at Thr18. Mol Cell Biol. 2009;29(11):2935-2944.
14. Yeh YH, Huang YF, Lin TY, Shieh SY. The cell cycle checkpoint kinase CHK2 mediates DNA damage-induced stabilization of TTK/hMps1. Oncogene. 2009;28(10):1366-1378.
15. Zhu S, Wang W, Clarke DC, Liu X. Activation of Mps1 promotes transforming growth factor-beta-independent Smad signaling. J Biol Chem. 2007;282(25):18327-18338.
16. Nishizaki T, Harada K, Kubota H, et al. Chromosome instability in malignant astrocytic tumors detected by fluorescence in situ hybridization. J Neurooncol. 2002;56(2):159-165.
17. Zeng WF, Navaratne K, Prayson RA, Weil RJ. Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme. J Clin Pathol. 2007;60(2):218-221.
18. Lengauer C, Kinzler KW and Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396(6712):643-649.
19. Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res. 1991;51(8):2212-2222.
20. Jordan MA, Thrower D, Wilson L. Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis. J Cell Sci. 1992;102(Pt 3):401-416.
21. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A. 1993;90(20):9552-9556.
22. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets. 2003;3(1):1-19.
23. Goncalves A, Braguer D, Kamath K, et al. Resistance to taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci U S A. 2001;98(20):11737-11742.
24. Colombo R, Caldarelli M, Mennecozzi M, et al. Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase. Cancer Res. 2010;70(24):10255-10264.
25. Janssen A, Kops GJ, Medema RH. Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. Proc Natl Acad Sci U S A. 2009;106(45):19108-19113.
26. Kwiatkowski N, Jelluma N, Filippakopoulos P, et al. Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. Nat Chem Biol. 2010;6(5):359-368.
27. Dorer RK, Zhong S, Tallarico JA, et al. A small-molecule inhibitor of Mps1 blocks the spindle-checkpoint response to a lack of tension on mitotic chromosomes. Curr Biol. 2005;15(11):1070-1076.
28. Sun L, Hui AM, Su Q, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell. 2006;9(4):287-300.
29. Hewitt L, Tighe A, Santaguida S, et al. Sustained Mps1 activity is required in mitosis to recruit O-Mad2 to the Mad1-C-Mad2 core complex. J Cell Biol. 2010;190(1):25-34.
30. Lan W, Cleveland DW. A chemical tool box defines mitotic and interphase roles for Mps1 kinase. J Cell Biol. 2010;190(1):21-24.
31. Freije WA, Castro-Vargas FE, Fang Z, et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 2004;64(18):6503-6510.
32. Bredel M, Bredel C, Juric D, et al. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res. 2005;65(19):8679-8689.
33. National Cancer Institute. 2005. REMBRANDT Home Page. http://rembrandt.nci.nih.gov. Accessed May 2, 2013.
34. Fisk HA, Mattison CP, Winey M. Human Mps1 protein kinase is required for centrosome duplication and normal mitotic progression. Proc Natl Acad Sci U S A. 2003;100(25):14875-14880.
35. Wakimoto H, Kesari S, Farrell CJ, et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009;69(8): 3472-3481.
36. Kops GJ, Foltz DR, Cleveland DW. Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci U S A. 2004;101(23):8699-8704.
37. Michel L, Diaz-Rodriguez E, Narayan G, et al. Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells. Proc Natl Acad Sci U S A. 2004;101(13):4459-4464.
38. Kim M, Liao J, Dowling ML, et al. TRAIL inactivates the mitotic checkpoint and potentiates death induced by microtubule-targeting agents in human cancer cells. Cancer Res. 2008;68(9):3440-3449.
39. Lee EA, Keutmann MK, Dowling ML, et al. Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells. Mol Cancer Ther. 2004;3(6):661-669.
40. Soffietti R, Ruda R, Bradac GB, Schiffer D. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery. 1998;43(5):1066-1073.
41. Nieder C, Mehta MP, Jalali R. Combined radio-and chemotherapy of brain tumours in adult patients. Clin Oncol (R Coll Radiol). 2009;21(7):515-524.
42. Aydin B, Patil M, Bekele N, Wolff JE. Vincristine in high-grade glioma. Anticancer Res. 2010;30(6):2303-2310.
43. Gravendeel LA, Kouwenhoven MC, Gevaert O, et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res. 2009;69(23):9065-72. Stroke